fda warning letters compounded semaglutide tirzepatide september 2025 versions of (Mounjaro, Zepbound) containing vitamin B12 pose a potential safety risk to the public, Eli Lilly warned in an open letter on Thursday. Following laboratory testing, the drugmaker said FDA warns telehealth providers over

The REDEFINE Phase 3 program directly addressed this, showing CagriSema achieved 20.4% weight loss versus lesser results with semaglutide alone, cagrilintide alone, and placebo

Prescription by Algorithm: The Ethical and Legal Questions Behind GLP-1 Advertising An influencer pitch for a GLP-1 weight-loss drug revealed a troubling shift in how prescriptions are marketed and obtained online

Smaller portions consumed consistently add up to substantial daily intake

Despite producing nearly 10 percentage points more weight loss, Retatrutide causes less nausea, less vomiting, and similar rates of other gastrointestinal symptoms

The phase 2 trial tested different starting dose strategies and found that slower titration reduced side effects but also delayed the onset of maximum weight loss

This was solved once Collip found a way to remove contaminants from the extract